Dr. Thanh Hue Dellinger, MD

Dr. Dellinger practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Dellinger's NPI, 1073730891, was assigned on April 20, 2007. Dr. Dellinger graduated from UC Irvine School of Medicine in 2004. Dr. Dellinger holds California license A103331.

Dr. Dellinger's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Dellinger's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Dellinger to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dellinger practices. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Dellinger's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Dellinger is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Dellinger's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists hysterectomy among the conditions Dr. Dellinger treats.

CMS data shows 516 Medicare services from Dr. Dellinger across 5 procedure codes in 2024, for 171 Medicare patients. Medicare paid $35,975 for them.

CMS counts 171 Medicare patients who saw Dr. Dellinger in 2024. The largest group is 65 to 74, with 91 patients. 74% of them have high blood pressure, and 65% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dellinger's median patient age at 64, with 99% women.

In 2024, Dr. Dellinger wrote 66 Medicare Part D claims for 32 patients. 95% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $193 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Dellinger for performance year 2024, reported as part of a group. Dr. Dellinger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dellinger as offering telehealth. CMS counts 18 procedures of removal of the uterus by Dr. Dellinger, more than 91% of the clinicians it reports for that procedure.

Dmand AI links 73 papers to Dr. Dellinger, published from 2012 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Ovarian Neoplasms, Peritoneal Neoplasms and Cell Line, Tumor. Dr. Dellinger has published most often in Ann Surg Oncol. Dr. Dellinger's most frequent co-authors are Ernest S. Han, MD, Mark Wakabayashi, MD and Mustafa Raoof, MD.

Dmand AI links Dr. Dellinger to 4 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Appendiceal Neoplasms, Endometrial Hyperplasia and Fallopian Tube Diseases. City of Hope Medical Center sponsors the most, 4.

CMS Open Payments shows 21 general payments to Dr. Dellinger from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. AstraZeneca Pharmaceuticals LP paid the most, $218.

Dr. Dellinger graduated from UC Irvine School of Medicine in 2004. Dr. Dellinger is a member of ASCO.

Dr. Dellinger is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.